Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proof-of concept study of NVG-2089 in patients with inflammatory myopathies and severe dermatologic autoimmune diseases.

Next Previous
Trial Profile

Proof-of concept study of NVG-2089 in patients with inflammatory myopathies and severe dermatologic autoimmune diseases.

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NVG 2089 (Primary)
  • Indications Autoimmune disorders; Myositis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Nuvig Therapeutics

Most Recent Events

  • 05 Dec 2024 According to a Nuvig Therapeutics media release, company announced the closing of a $161 million Series B financing, proceeds from the Series B financing will support clinical proof-of-concept studies for NVG-2089.
  • 15 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top